Evidence map›Paper›PMID 30546443›Full record

ArticleOncology letters2018

ALK expression favorably impacts the prognosis of

Simona Osella-Abate, Elisabetta Mereu, Elisa Pellegrino, Elisa Bergaggio, Simone Ribero, Luca Bertero, Francesco Lisa, Maria Teresa Fierro, Mauro Giulio Papotti, Roberto Piva

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Simona Osella-AbateDepartment of Medical Sciences, Pathology Unit, University of Torino, I-10126 Torino, Italy.
Elisabetta MereuDepartment of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies, University of Torino, I-10126 Torino, Italy.
Elisa PellegrinoDepartment of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies, University of Torino, I-10126 Torino, Italy.
Elisa BergaggioDepartment of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies, University of Torino, I-10126 Torino, Italy.
Simone RiberoDepartment of Medical Sciences, Dermatology Unit, University of Torino, I-10126 Torino, Italy.
Luca BerteroDepartment of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies, University of Torino, I-10126 Torino, Italy.
Francesco LisaDepartment of Medical Sciences, Dermatology Unit, University of Torino, I-10126 Torino, Italy.
Maria Teresa FierroDepartment of Medical Sciences, Dermatology Unit, University of Torino, I-10126 Torino, Italy.
Mauro Giulio PapottiDepartment of Oncology, Pathology Unit, University of Torino, I-10126 Torino, Italy.
Roberto PivaDepartment of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies, University of Torino, I-10126 Torino, Italy.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies reported the expression of anaplastic lymphoma kinase (ALK) in malignant melanomas. The aim of this study was to investigate whether ALK expression is associated with specific clinical and molecular characteristics of melanoma metastases, and to evaluate its correlation with survival outcomes. Seventy-one patients with metastatic melanoma were investigated. Clinical features and survival outcomes were analyzed and correlated to ALK expression, as detected by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction, and to the mutational status of

Indexed as

ALKmetastatic melanomaNRAS

Identifiers

PMID30546443
PMCPMC6256323
OpenAlexW2895812435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.